BofA Lowers Price Target for Madrigal Pharmaceuticals (MDGL)

Bank of America lowered its price target for Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to $542 from $550 while maintaining a Neutral rating on the stock. The firm cited concerns about sustaining momentum following Rezdiffra's launch in MASH and reduced revenue forecasts for 2028.

By Fatima Gulzar Wed, July 8, 2026 at 10:20 PM GMT+3 1 min read · Yahoo Finance · July 8, 2026, 19:20 UTC

BofA Lowers Price Target for Madrigal Pharmaceuticals (MDGL)

Tickers: $MDGL

Topics: Biotech MASH (Metabolic-Associated Steatohepatitis) Pharmaceuticals siRNA Collaboration

Read the full article at Yahoo Finance

More World news

Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC
Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC